Key clinical point: Higher levels of several immune markers confer better response and prognosis with trastuzumab plus pertuzumab in patients with HER2-positive breast cancer.
Major finding: Topoisomerase II-alpha amplification and higher messenger RNA expression of a three-gene signature each predicted better prognosis (hazard ratios, 0.68 and 0.91, respectively).
Study details: A nested case-control assessment of 1,023 patient samples from the phase 3 APHINITY trial of patients with HER2-positive breast cancer.
Disclosures: Dr. Krop reported relationships – including employment, leadership, and stock ownership – with AMAG, as well as honoraria from Genentech/Roche; consulting or advisory roles with Context Therapeutics, Daiichi Sankyo, Genentech/Roche, MacroGenics, Seattle Genetics, and Taiho Pharmaceutical; and research funding from Genentech and Pfizer to his institution.
Krop IE et al. ASCO 2019, Abstract 1012.